PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY
EHA Learning Center, Paula Rodriguez-Otero, 182070
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH DELETION 5Q OR MONOSOMY 5: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (ALWP) OF THE EBMT
EHA Learning Center, Xavier Poiré, 182085
T-CELL RECEPTOR Β (TRB) REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) ON BLINATUMOMAB TREATMENT.
EHA Learning Center, Henrik Knecht, 182090
DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES
EHA Learning Center, Francesca Vinchi, 182100
CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND TUMOR GROWTH IN MICE
EHA Learning Center, Tobias Haas, 182105
CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
EHA Learning Center, Loretta Nastoupil, 182059
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA
EHA Learning Center, Pier Luigi Zinzani, 182064
COMPARISON OF DENOSUMAB (DMB) WITH ZOLEDRONIC ACID (ZA) FOR THE TREATMENT OF BONE DISEASE IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; AN INTERNATIONAL, RANDOMIZED, DOUBLE BLIND TRIAL
EHA Learning Center, Evangelos Terpos, 182069
MOLECULAR RESPONSE TO HYDROXYUREA AND ROPEGINTERFERON ALFA-2B IN THE PROUD-PV RANDOMIZED PHASE 3 TRIAL
EHA Learning Center, Jean-Jacques Kiladjian, 182074
SORAFENIB MAINTENANCE IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANT
EHA Learning Center, Betül Oran, 182079
CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR ADULTS WITH PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Sebastian Giebel, 182084
POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14,ISRCTN 66541317)
EHA Learning Center, Dina Okasha, 182089
LETERMOVIR (LET) FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
EHA Learning Center, Rafael Duarte, 182094
INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
EHA Learning Center, Aaron Weigl, 182099
MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES
EHA Learning Center, Antonio Galleu, 182104
VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL
EHA Learning Center, Stephan Stilgenbauer, 182058
EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY
EHA Learning Center, Pier Luigi Zinzani, 182063
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
EHA Learning Center, Charlotte Pawlyn, 182068
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
EHA Learning Center, C Harrison, 182073
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY
EHA Learning Center, Charles Craddock, 182078
IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE
EHA Learning Center, Livia Giannoni, 182083
MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM
EHA Learning Center, Monika Brüggemann, 182088
INFECTION-RELATED MORTALITY (IRM) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM
EHA Learning Center, Alessandra Forcina, 182093
UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT
EHA Learning Center, Gianluca De Rosa, 182098
GENERATION OF MEMORY STEM T CELLS (TSCM) MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES
EHA Learning Center, Laura Escribà, 182103
THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY
EHA Learning Center, Peter Hillmen, 182057
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
EHA Learning Center, Wolfgang Hiddemann, 182062
TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION (SCT)
EHA Learning Center, Paul Richardson, 182067
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
EHA Learning Center, Jason R. Gotlib, 182072
FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70
EHA Learning Center, Ana Garrido, 182077
GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Zinaida Peric, 182082
PROGNOSTIC IMPACT OF ADDITIONAL MOLECULAR LESIONS IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
EHA Learning Center, Anna Lucia Fedullo, 182087
CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIAA RANDOMIZED STUDY BY THE SWEDISH CLL GROUP
EHA Learning Center, Tobias Svensson, 182092
IDENTIFICATION OF GUANOSINE 5ʹ-DIPHOSPHATE AS POTENTIAL IRON MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY
EHA Learning Center, Stanzin angmo, 182097
CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY
EHA Learning Center, Nicholas HUNTINGTON, 182102
IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP
EHA Learning Center, Carolina Moreno Atanasio, 182056
COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY
EHA Learning Center, Judith Trotman, 182061
PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA
EHA Learning Center, Irene Ghobrial, 182066
RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL
EHA Learning Center, Martin Greisshammer, 182071
LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY
EHA Learning Center, Marius Flasinski, 182076
21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)
EHA Learning Center, Karl Staser, 182081
IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Masafumi Seki, 182086
DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)
EHA Learning Center, Ildefonso Espigado, 182091
LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION.
EHA Learning Center, Sandro Altamura, 182096
A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL
EHA Learning Center, Mark Walters, 182101
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN
EHA Learning Center, Maria Gabelli, 182025
PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Partow Kebriaei, 182026
DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM
EHA Learning Center, Paul Richardson, 182027
GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS
EHA Learning Center, Gudrun Strauss, 182041
IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS
EHA Learning Center, Maria Fernandez-Garcia, 182042
EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFCATIONS.
EHA Learning Center, Isabel Alvarez Laderas, 182043
RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL
EHA Learning Center, Yuan Kong, 181794
PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING
EHA Learning Center, Felix Seyfried, 181795
CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA
EHA Learning Center, Lucia Fernandez, 181796
A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR
EHA Learning Center, Africa Gonzalez-Murillo, 181797
KTE-C19 CHIMERIC ANTIGENRECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3
EHA Learning Center, Bijal Shah, 181810
EXPOSURE-ADJUSTED ADVERSE EVENTS COMPARING BLINATUMOMAB WITH STANDARD OF CARE CHEMOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A RANDOMIZED PHASE 3 STUDY
EHA Learning Center, Max S.Topp, 181811
FACTORS ASSOCIATED WITH STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN VERSUS CONVENTIONAL CHEMOTHERAPY
EHA Learning Center, Matthias Stelljes, 181812
DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS
EHA Learning Center, Sharlene Adams, 181813
NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA
EHA Learning Center, I-Jun Lau, 181827
CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Sneha CHITRE, 181828
TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML
EHA Learning Center, Iris Uras, 181829
CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.
EHA Learning Center, Mayte Medrano, 181830
HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Sarah Bertoli, 181844
NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE - IMPACT OF AGE ON MUTATIONAL LOAD
EHA Learning Center, Lisa Pleyer, 181845
PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY
EHA Learning Center, Sigrid Machherndl-Spandl, 181846
EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT WITH GILTERITINIB
EHA Learning Center, Mark Levis, 181847
SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA
EHA Learning Center, Francesca Fioredda, 181862
TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS
EHA Learning Center, Constantijn J.M. Halkes, 181863
IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
EHA Learning Center, Xuying Pei, 181864
DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY
EHA Learning Center, Mirkka Schaller, 181865
THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Mhairi Copland, 181878
SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS
EHA Learning Center, Jun Toda, 181879
TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT
EHA Learning Center, Anne-Sophie Bouillon, 181880
GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS PREEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION TO BLASTIC PHASE INDEPENDENTLY OF BCR-ABL1 MUTATIONS
EHA Learning Center, Marcin Machnicki, 181881
COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS
EHA Learning Center, Simona Bernardi, 181894
OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA
EHA Learning Center, Chetasi Talati, 181895
EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS
EHA Learning Center, Juan Luis Steegmann, 181896
GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB
EHA Learning Center, Giovanni Caocci, 181897
NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES
EHA Learning Center, Antonia Rotolo, 181911
A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS
EHA Learning Center, Yasushi Kasahara, 181912
NKP30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT MODELS
EHA Learning Center, Udo Hartwig, 181913
REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN WALDENSTROM MACROGLOBULINEMIA : A RETROSPECTIVE STUDY FROM 163 PATIENTS
EHA Learning Center, Caroline Protin, 181928
MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL
EHA Learning Center, Tatsuo Oyake, 181929
ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE ASPERGILLOSIS
EHA Learning Center, Frederic Ries, 181930
PRECLINICAL MODELING OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Kevin Rouault-Pierre, 181944
MYELODYSPLASTIC SYNDROMES WITH IRON OVERLOAD ARE CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON CHELATION. A FISM STUDY
EHA Learning Center, Daniela Cilloni, 181945
V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTITUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Yasuko Kuribayashi-Hamada, 181946
PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
EHA Learning Center, Surbhi Sidana, 181960
RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY
EHA Learning Center, Joy Ho, 181961
VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Shaji K Kumar, 181962
MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS
EHA Learning Center, Takaaki Maekawa, 181976
ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID- MICE
EHA Learning Center, Taghi Manshouri, 181977
ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS
EHA Learning Center, Hiraku Takei, 181978
EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS
EHA Learning Center, Nicola Polverelli, 181992
TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY
EHA Learning Center, Steffen Koschmieder, 181993
SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B - AN UPDATE FROM THE PEGINVERA STUDY
EHA Learning Center, Heinz Gisslinger, 181994
BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES
EHA Learning Center, Nuria Revilla, 182008
SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS
EHA Learning Center, Silvia Cantoni, 182009
THROMBOEMBOLIC EVENT MANAGEMENT AND OUTCOMES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ELTROMBOPAG (EPAG): RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Mansoor N Saleh, 182010